Replies to post #14493 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Yes PAR was definitely responsible for the FDA's additional FocalinXR BE requirement and logic strongly suggests that PAR didn't sign the licensing agreement with IPCI on FocalinXR to not make money right!

So given the timeframe involved it's logical to assume/expect that FDA approval on the additional FocalinXR strengths should be coming soon...especially given the market share PAR's been able to capture and maintain on just the 1st 2 approved FocalinXR strengths!